The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain.

In agreement with results from the short-term model, concomitant administration of unencapsulated rosiglitazone and rotenone for 60 days (RCG60) resulted in a protective effect in the SN which did not achieve significance and was comparable to that achieved on administration of liposomes in the absence of rosiglitazone (Lipo60) (Fig. 5b ).

also in 1,397 other papers